Joint & Tissue Recovery Peptide Stack UAE 2026: BPC-157 + TB-500 Protocol
Joint & Tissue Recovery Peptide Stack UAE 2026: BPC-157 + TB-500 Protocol
BPC-157 and TB-500 are the two most researched healing peptides available — and together they form the most studied and widely used recovery stack in research. They have complementary, non-overlapping mechanisms: BPC-157 drives localised structural repair and angiogenesis; TB-500 promotes systemic actin regulation, anti-inflammatory signalling, and systemic tissue regeneration. Used together, they address recovery from multiple angles simultaneously.
Why BPC-157 + TB-500 Work Better Together
| Property | BPC-157 | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Primary mechanism | Growth factor upregulation (VEGF, EGF), angiogenesis, collagen production | Actin sequestration, cell migration, anti-inflammatory, stem cell mobilisation |
| Action radius | Local to injection site + systemic | Systemic — travels throughout the body |
| Tendon repair | Strong — promotes tenocyte proliferation and collagen alignment | Moderate — promotes cell migration to injury site |
| Muscle repair | Moderate | Strong — actin-based myocyte repair |
| Nerve repair | Strong — promotes neurite growth | Moderate |
| Anti-inflammatory | Moderate (indirect) | Strong — direct NF-κB suppression |
| GI protection | Strong (unique to BPC-157) | Minimal |
Standard Recovery Protocol
BPC-157 Dosing
Dose: 250–500 mcg subcutaneous (near injury site preferred) or intramuscular
Frequency: Once or twice daily
Duration: 4–8 weeks for acute injuries; longer for chronic conditions
Note: Injectable closest to the injury site produces the most targeted tissue effect. Systemic SC injection also works for non-localised or internal injuries (gut, systemic).
TB-500 Dosing
Loading phase: 5–10 mg/week for 4–6 weeks (split into 2 injections)
Maintenance phase: 2–5 mg/week ongoing
Frequency: 2× per week SC injection
Note: TB-500 is systemic — injection site does not need to be near the injury. Subcutaneous anywhere is effective.
Injury-Specific Protocols
| Injury Type | BPC-157 Dose | TB-500 Dose | Priority |
|---|---|---|---|
| Tendon/ligament tear | 500 mcg 2×/day near site | 10 mg/week loading | Both equally important |
| Muscle tear/strain | 500 mcg 1×/day | 10 mg/week loading | TB-500 priority for muscle |
| Joint inflammation | 250–500 mcg 1–2×/day | 5 mg/week | BPC-157 priority for joints |
| Gut/GI issues | 250 mcg 2×/day (or oral capsule) | Optional add-on | BPC-157 only sufficient for GI |
| Nerve damage | 500 mcg 1–2×/day near site | 5 mg/week | BPC-157 priority for nerve |
Available as Pre-Mixed Combination
For convenience, BPC-157 + TB-500 is available as a pre-mixed 5mg/5mg vial — eliminating the need to reconstitute and administer two separate injections. This combination is particularly useful for general injury recovery research where both mechanisms are desired simultaneously.
Products in This Stack
Shop the Recovery Stack in Dubai
BPC-157, TB-500, and BPC-157 + TB-500 pre-mix — cGMP sourced, ≥99% purity.
Shop BPC-157 + TB-500 MixFAQ
Yes — they can be taken simultaneously (as separate injections or as the pre-mixed combination). There are no known interactions. The pre-mixed BPC-157 + TB-500 vial is specifically formulated for this purpose.
In animal research models, significant tendon healing improvements are measurable within 7–14 days. Human research protocols typically run for 4–8 weeks for acute tendon injuries, with pain reduction often reported within the first 1–2 weeks. Chronic tendon conditions may require 8–12 weeks of consistent administration.
CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.
Shop Bacteriostatic Water →Disclaimer: This article is for educational and research purposes only. All compounds mentioned are research peptides not approved for human therapeutic use by UAE MOHAP or the FDA. Stack protocols described represent research designs, not medical prescriptions. Consult a licensed UAE healthcare professional before beginning any protocol.
Written by Core Sup Research Team
Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE
Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.
Last reviewed: April 2026 · About Core Sup
